Bepotastine besilate ophthalmic solution 1.5% clears the hurdle for allergic ocular itching

July 1, 2009
Optometry Times Staff Reports

The FDA Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) for treating ocular itching associated with allergic conjunctivitis.

Key Points

Irvine, CA-The FDA Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) for treating ocular itching associated with allergic conjunctivitis.

The FDA still is required to approve the application and has set a date of Sept. 12 to take further action on the drug.

Bepotastine besilate is an eye-drop treatment that acts as a non-sedating, highly selective antagonist of the histamine receptor. It has been approved in Japan since 2000 to treat allergic rhinitis and urticaria/pruritus.

Related Content:

News